Media

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

August 6, 2026

RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

August 4, 2026

RenovoRx today announced it will participate in a JonesTrading webinar with oncology key opinion leaders (KOLs) and Shaun Bagai, Chief Executive Officer of RenovoRx, on August 13, 2026 at 1:30…

Magnifying glass over financial documents

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

July 29, 2026

RenovoRx today announced that it will host its second quarter 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. ET.

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

June 11, 2026

RenovoRx today announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports.

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

June 4, 2026

RenovoRx today announced that Chief Executive Officer, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, being held June 23-24, 2026.

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026

RenovoRx today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

May 26, 2026

RenovoRx today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial has been published online in connection with the 2026…

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

May 19, 2026

RenovoRx today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance Global Partners (AGP) Annual Healthcare Company Showcase, hosted by Scott…

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

May 14, 2026

RenovoRx today announced its financial results for the first quarter ended March 31, 2026, and is providing shareholders with a business update.

People in suits going over financial documents

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

April 29, 2026

RenovoRx today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be…

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

April 23, 2026

RenovoRx is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been…

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

April 14, 2026

RenovoRx today announced that a clinical data abstract submitted by experts from Moffitt Cancer Center was presented at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto,…

* Individual results may vary.

The Most Innovative Medical Device Companies of 2026

May 8, 2026

Why RenovoRx, Medtronic, Uresta, and Cionic are among the 10 most innovative companies making medical devices right now.

Mark Voll Joins RenovoRx as Chief Financial Officer

February 19, 2026

RenovoRx Inc. has welcomed a new member to its senior leadership team, hiring Mark Voll as chief financial officer (CFO), effective Feb. 1.

Why Commercial Discipline Starts Long Before Launch

February 17, 2026

Shaun Bagai is the CEO of RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs.

Interview with Shaun Bagai: Revolutionary Cancer Treatment, Startup Success, & Medtech Mentorship

January 23, 2026

Shaun Bagai is the CEO and Director of RenovoRx, and a seasoned MedTech leader whose path began with a Silicon Valley startup internship that ultimately pulled him away from medical…

Nanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer

January 13, 2026

A major breakthrough in cancer drug delivery took place in 1995, when the FDA approved the first nanodrug, Doxil—a liposomal formulation of doxorubicin engineered to preferentially accumulate in tumors. Since…

Revolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai

November 25, 2025

In this compelling episode of MedTech 101, host Rodney Moses sits down with RenovoRx CEO Shaun Bagai to explore the latest breakthroughs in cancer treatment. The conversation opens with a…

First Patient Treated in RenovoCath Clinical Trial

November 10, 2025

RenovoRx Inc.’s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone with the first patient treatment at the University of Vermont Cancer…

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

September 29, 2025

Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.

From Trials to Hope: A New Approach to Treating Pancreatic Cancer

September 27, 2025

Shaun Bagai, CEO of RenovoRx, joined us to discuss an innovative approach delivering chemo directly to pancreatic tumors. By targeting the cancer more precisely, this treatment may reduce side effects…

RenovoRx Panther Study Progresses with First Clinical Procedure

September 26, 2025

RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont Cancer Center, and two additional sites—Baptist Health Miami Cancer Institute and…

How Skipping The CRO Helped RenovoRx Get Closer To Patients

September 24, 2025

In this Q&A, RenovoRx Chief Clinical Officer Leesa Gentry explains why they decided to forgo a CRO partner, discusses their in-house expertise, and shares how the decision helped them get…

PharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma

August 29, 2025